nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.04.2011 | Therapy In Practice

Postinflammatory Hyperpigmentation

Etiologic and Therapeutic Considerations

verfasst von: Valerie D. Callender, MD, Sharleen St. Surin-Lord, Erica C. Davis, Marissa Maclin

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Postinflammatory hyperpigmentation (PIH) is a reactive hypermelanosis and sequela of a variety of inflammatory skin conditions. PIH can have a negative impact on a patient’s quality of life, particularly for darker-skinned patients. Studies show that dyschromias, including PIH, are one of the most common presenting complaints of darker-skinned racial ethnic groups when visiting a dermatologist. This is likely due to an increased production or deposition of melanin into the epidermis or dermis by labile melanocytes. A variety of endogenous or exogenous inflammatory conditions can culminate in PIH and typically most epidermal lesions will appear tan, brown, or dark brown while dermal hypermelanosis has a blue-gray discoloration.

Depigmenting agents target different steps in the production of melanin, most commonly inhibiting tyrosinase. These agents include hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice (glycyrrhiza) extracts. Other agents include retinoids, mequinol, ascorbic acid (vitamin C), niacinamide, N-acetyl glucosamine, and soy, and these products depigment by different mechanisms. Certain procedures can also be effective in the treatment of PIH including chemical peeling and laser therapy. It is important to note that these same therapeutic modalities may also play a role in causing PIH. Lastly, those lesions that are not amenable to medical or surgical therapy may experience some improvement with cosmetic camouflage.

Grimes PE. Management of hyperpigmentation. Semin Cutan Med Surg 2009; 28: 77–85PubMedCrossRef

Halder RM, Grimes PE, McLaurin CI, et al. Incidence of common dermatoses in a predominately black dermatologic practice. Cutis 1983; 32: 388–90PubMed

Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a comparative practice survey. Cutis 2007; 80: 387–94PubMed

Sanchez MR. Cutaneous diseases in Latinos. Dermatol Clin 2003; 21: 689–97PubMedCrossRef

Nordlund JJ, Abdel-Malek ZA. Mechanisms for post-inflammatory hyperpigmentation and hypopigmentation. In: Bagnara JT, editor. Advances in pigment cell research: proceedings of symposia and lectures from the Thirteenth International Pigment Cell Conference held in Tucson, AZ, October 5-9, 1986. New York: Liss, 1988: 219–39

Tomita Y, Maeda K, Tagami H. Melanocyte-stimulating properties of arachidonic acid metabolites: possible role in postinflammatory pigmentation. Pigment Cell Res 1992; 5: 357–61PubMedCrossRef

Ortonne J. Retinoic acid and pigment cells: a review of in-vitro and in-vivo studies. Br J Dermatol 1992; 127 Suppl. 41: 43–7PubMedCrossRef

Taylor SC, Grimes PE, Lim J, et al. Postinflammatory hyperpigmentation. J Cutan Med Surg 2009; 13: 183–91PubMed

Lacz NL, Vafaie J, Kihiczac NI, et al. Postinflammatory hyperpigmentation: a common but troubling condition. Int J Dermatol 2004; 4: 362–5CrossRef

10.

Masu S, Seiji M. Pigmentary incontinence in fixed drug eruptions: histologic and electron microscopic findings. J Am Acad Dermatol 1983; 8: 525–32PubMedCrossRef

11.

Ruiz-Maldonado R, Orozco-Covarrubias ML. Postinflammatory hypopigmentation and hyperpigmentation. Semin Cutan Med Surg 1997; 16: 36–43PubMedCrossRef

12.

Chang MW. Disorders of hyperpigmentation. In: Jorizzo JL, Rapini RP, Bolognia JL, editors. Dermatology. 2nd ed. New York: Mosby Elsevier, 2009: 333–89

13.

Stratigos AJ, Katsambas AD. Optimal managment of recalcitrant disorders of hyperpigmentation in dark-skinned patients. Am J Clin Dermatol 2004; 5: 161–8PubMedCrossRef

14.

Cook-Bolden F. The efficacy and tolerability of combination cream containing 4% hydroquinone in the treatment of postinflammatory hyperpigmentation in skin types IV-VI. Cosmetic Dermatol 2004; 17: 149–55

15.

Cook-Bolden FE, Hamilton SF. An open-label study of the efficacy and tolerability of microencapsulated hydroquinone 4% and retinol 0.15% with antioxidants for the treatment of hyperpigmentation. Cutis 2008; 81: 365–71PubMed

16.

Grimes PE. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. Cutis 2004; 74: 362–8PubMed

17.

Taylor SC, Callender VD. A multicenter, 12-week, phase 3b trial: a combination solution of mequinol 2%/tretinoin 0.01% vs hydroquinone 4% cream in the treatment of mild to moderate postinflammatory hyperpigmentation [abstract]. J Am Acad Dermatol 2006; 54 Suppl.: AB194

18.

Bulengo-Ransby SM, Griffiths C, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med 1993; 328: 1438–43PubMedCrossRef

19.

Jacyk AK, Mpofu P. Adapalene gel 0.1%for topical treatment of acne vulgaris in African patients. Cutis 2001; 68: 48–54PubMed

20.

Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis 2006; 77: 45–50PubMed

21.

Lowe NJ, Rizk D, Grimes P, et al. Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clin Ther 1998; 20: 945–59PubMedCrossRef

22.

Kakita LS, Lowe NJ. Azelaic acid and glycolic acid combination therapy for facial hyperpigmentation in darker-skinned patients: a clinical comparison with hydroquinone. Clin Ther 1998; 20: 960–70PubMedCrossRef

23.

Finkey MB, Herndon J, Stephens T, et al. Soy moisturizer SPF 15 improves dyschromia [poster]. J Am Acad Dermatol 2005; 52 Suppl.: P170

24.

Sah A, Stephens TJ, Kurtz ES. Topical acne treatment improves postacne postinflammatory hyperpigmentation (PIH) in skin of color [poster]. J Am Acad Dermatol 2005; 52 Suppl.: P25

25.

Halder RM, Nandekar MA, Neal KW. Pigmentary disorders in pigmented skins. In: Halder RM, editor. Dermatology and dermatological therapy of pigmented skins. Boca Raton (FL): CRC/Taylor & Francis, 2006: 91–114

26.

Jimbow K, Minamitsuji Y. Topical therapies for melasma and disorders of hyperpigmentation. Dermatol Ther 2001; 14: 35–45CrossRef

27.

Yoshimura K, Harii K, Aoyama T, et al. A new bleaching protocol for hyperpigmentated skin lesions with a high concentration of all-trans retinoic acid aqueous gel. Aesthetic Plast Surg 1999; 23: 285–91PubMedCrossRef

28.

Yoshimura K, Harii K, Aoyama T, et al. Experience with a strong bleaching treatment for skin hyperpigmentation in Orientals. Plast Reconstr Surg 2000; 105: 1097–108PubMedCrossRef

29.

Ortonne JP, Passeron T. Melanin pigmentary disorders: treatment update. Dermatol Clin 2005; 23: 209–26PubMedCrossRef

30.

Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triplecombination agent for the treatment of facial melasma. Cutis 2003; 72: 67–72PubMed

31.

Chan R, Park KC, Lim MH, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol 2008; 159: 697–703PubMed

32.

Torok HM, Jones T, Rich P, et al. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Cutis 2005; 75: 57–62PubMed

33.

Grimes P, Kelly AP, Torok H, et al. Community-based trial of a triplecombination agent for the treatment of facial melasma. Cutis 2006; 77: 177–84PubMed

34.

Katsambas AD. RALGA (Diacneal), a retinaldehyde and glycolic acid association and postinflammatory hyperpigmentation in acne: a review. Dermatology 2005; 210 Suppl. 1: 39–45PubMedCrossRef

35.

Levin CY, Maibach H. Exogenous ochronosis: an update on clinical features, causative agents and treatment options. Am J Clin Dermatol 2001; 2: 213–7PubMedCrossRef

36.

Levitt J. The safety of hydroquinone: a dermatologist’s response to the 2006 Federal Register. J Am Acad Dermatol 2007; 57: 854–72CrossRef

37.

Fleischer AB, Schwartzel EH, Colby SI, et al. The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies. J Am Acad Dermatol 2000; 42: 459–67PubMedCrossRef

38.

Draelos ZD. The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin effectively improves the appearance of solar lentigines in ethnic groups. J Cosmet Dermatol 2006; 5: 239–44PubMedCrossRef

39.

Ortonne JP, Camacho F, Wainwright N, et al. Safety and efficacy of combined use of 4-hydroxyanisole (mequinol) 2%/tretinoin 0.01% solution and sunscreen in solar lentigines. Cutis 2004; 74: 261–4PubMed

40.

Callender VD. A small open-label study of a 2% 4-hydroxyanisole and 0.01% tretinoin solution for the treatment of postinflammatory hyperpigmentation [poster]. J Am Acad Dermatol 2004; 50 Suppl.: P175CrossRef

41.

Piacquadio D, Farris P, Downie J, et al. Mequinol 2%/tretinoin 0.01% solution monotherapy and combination treatment of solar lentigines and postinflammatory hyperpigmentation [poster]. J Am Acad Dermatol 2004; 52 Suppl.: P145

42.

Winhoven SM, Ahmed I, Owen CM, et al. Postinflammatory hyperpigmentation in an Asian patient: a dramatic response to oral isotretinoin (13-cis-retinoic acid). Br J Dermatol 2005; 152: 368–9PubMedCrossRef

43.

Halder RM, Richards GM. Topical agents used in the management of hyperpigmentation. Skin Therapy Lett 2004; 9: 1–3PubMed

44.

Nguyen QH, Bui TP. Azelaic acid: pharmacokinetic and pharmacodynamic properties and its therapeutic role in hyperpigmentary disorders and acne. Int J Dermatol 1995; 34: 75–84PubMedCrossRef

45.

Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg 1999; 25: 282–4PubMedCrossRef

46.

Garcia A, Fulton JE. The combination of glycolic acid and hydroquinone or kojic acid for the treatment ofmelasma and related conditions. Dermatol Surg 1996; 22: 443–7PubMedCrossRef

47.

Grimes PE. Management of hyperpigmentation in darker racial ethnic groups. Semin Cutan Med Surg 2009; 28: 77–85PubMedCrossRef

48.

Serra-Baldrich E, Tribo MJ, Camarasa JG. Allergic contact dermatitis from kojic acid. Contact Dermatitis 1998; 39: 86–7PubMedCrossRef

49.

Nakagawa M, Kawai K, Kawai K. Contact allergy to kojic acid in skin care products. Contact Dermatitis 1995; 32: 9–13PubMedCrossRef

50.

Petit L, Pierard GE. Skin-lightening products revisited. Int J Cosmet Sci 2003; 25: 169–81PubMedCrossRef

51.

Zhu W, Gao J. The use of botanical extracts as topical skin-lightening agents for the improvement of skin pigmentation disorders. J Inv Dermatol Symp Proc 2008; 13: 20–4CrossRef

52.

Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther 2007; 20: 308–13PubMedCrossRef

53.

Maeda K, Fukuda M. Arbutin: mechanism of its depigmenting action in human melanocyte culture. J Pharmacol Exp Ther 1996; 276: 765–9PubMed

54.

Funayama M, Arakawa H, Yamamoto R, et al. Effects of alpha- and betaarbutin on activity of tyrosinases from mushroom and mouse melanoma. Biosci Biotechnol Biochem 1995; 59: 143–4PubMedCrossRef

55.

Boissy RE, Visscher M, de Long MA. Deoxyarbutin: a novel reversible tyrosinase inhibitorwith effective in vivo skin lightening potency. Exp Dermatol 2005; 14: 601–8PubMedCrossRef

56.

Hakozaki T, Minwalla L, Zhuang J, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression ofmelanosome transfer. Br J Dermatol 2002; 147: 20–31PubMedCrossRef

57.

Kimball AB, Kaczvinsky JR, Li J, et al. Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N-acetyl glucosamine: results of a randomized, doubleblind, vehicle-controlled trial. Br J Dermatol 2010; 162: 435–41PubMedCrossRef

58.

Bissett DL, Miyamoto K, Sun P, et al. Topical niacinamide produces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin. Int J Cosmet Sci 2004; 26: 231–8PubMedCrossRef

59.

Bissett DL, Robinson LR, Raleigh PS, et al. Reduction in the appearance of facial hyperpigmentation by topical N-acetyl glucosamine. J Cosmet Dermatol 2007; 6: 20–6PubMedCrossRef

60.

Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J Dermatol 2004; 43: 604–7PubMedCrossRef

61.

Farris PK. Topical vitamin C: a useful agent for treating photoaging and other dermatologic conditions. Dermatol Surg 2005; 31: 814–8PubMedCrossRef

62.

Fu B, Li H, Wang X, et al. Isolation and identification of flavonoids in licorice and a study of their inhibitory effects on tyrosinase. J Agric Food Chem 2005; 53: 7408–14PubMedCrossRef

63.

Yokota T, Nishio H, Kubota Y, et al. The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. Pigment Cell Res 1998; 11: 355–61PubMedCrossRef

64.

Amer M, Metwalli M. Topical liquiritin improves melasma. Int J Dermatol 2000; 39: 299–301PubMedCrossRef

65.

Paine C, Sharlow E, Liebel F, et al. An alternative approach to depigmentation by soybean extracts via inhibition of the PAR-2 pathway. J Invest Dermatol 2001; 116: 587–95PubMedCrossRef

66.

Grimes PE, Rendon MI, Pellerano J. Superficial chemical peels. In: Grimes PE, editor. Aesthetics and cosmetic surgery for darker skin types. Philadelphia (PA): Lippincott Williams & Wilkins, 2008: 154–69

67.

Song JY, Kang HA, Kim MY, et al. Damage and recovery of skin barrier function after glycolic acid chemical peeling and crystal microdermabrasion. Dermatol Surg 2004; 30: 390–4PubMedCrossRef

68.

Burns RL, Prevost-Blank PL, Lawry MA, et al. Glycolic acid peels for postinflammatory hyperpigmentation in black patients: a comparative study. Dermatol Surg 1997; 23: 171–4PubMedCrossRef

69.

Roberts WE. Chemical peeling in ethnic/dark skin. Dermatol Ther 2004; 17: 196–205PubMedCrossRef

70.

Ahn HH, Kim IH. Whitening effect of salicyclic acid peels in Asian patients. Dermatol Surg 2006; 32: 372–5PubMedCrossRef

71.

Tanzi EL, Alster TS. Cutaneous laser surgery in darker skin phototypes. Cutis 2004; 73: 27–30

72.

Alster TS, Tanzi EL. Laser surgery in dark skin. Skinmed 2003; 2: 80–5PubMedCrossRef

73.

Macedo O, Alster TS. Laser treatment of darker skin tones: a practical approach. Dermatol Ther 2000; 13: 114–26CrossRef

74.

Halder RM, Nootheti PK. Ethnic skin disorders overview. J Am Acad Dermatol 2003; 48: 143–8CrossRef

75.

Terrel S, Aires D, Schweiger ES. Treatment of acne vulgaris using blue light photodynamic therapy in an African-American patient. J Drugs Dermatol 2009; 8: 669–71

76.

Rokhsar CK, Ciocon DH. Fractional photothermolysis for the treatment of postinflammatory hyperpigmentation after carbon dioxide laser resurfacing. Dermatol Surg 2009; 35: 535–7PubMedCrossRef

77.

Katz TM, Goldberg LH, Firoz BF, et al. Fractional photothermolysis for the treatment of postinflammatory hyperpigmentation. Dermatol Surg 2009; 35: 1844–8PubMedCrossRef

78.

Holme SA, Beattie PE, Fleming CJ. Cosmetic camouflage advice improves quality of life. Br J Dermatol 2002; 147: 946–9PubMedCrossRef

79.

Kent G. Testing a model of disfigurement: effects of a skin camouflage service on well-being and appearance anxiety. Psychol Health 2002; 17: 377–86CrossRef

80.

Antoniou C, Stefanaki C. Cosmetic camouflage. J Cosmet Dermatol 2006; 5: 297–301PubMedCrossRef

81.

Roberts NG, Nordlund JJ, Wright C. The corrective cover or camouflage clinic. Ear Nose Throat J 1989; 68: 480–2PubMed

82.

Rayner VL. Camouflage therapy. Dermatol Clin 1995; 13: 467–72PubMed

83.

Katoulis AC, Alevizou A, Bozi E, et al. A randomized, double-blind, vehiclecontrolled study of a preparation containing undecylenoyl phenylalanine 2% in the treatment of solar lentigines. Clin Exp Dermatol 2010; 35: 473–6PubMedCrossRef

84.

Kasraee B, Handjani F, Parhizgar A, et al. Topical methimazole as a new treatment for postinflammatory hyperpigmentation: report of the first case. Dermatology 2005; 211: 360–2PubMedCrossRef

85.

Tirado-Sanchez A, Santamaria-Roman A, Ponce-Olivera RM. Efficacy of dioic acid compared with hydroquinone in the treatment of melasma. Int J Dermatol 2009; 48: 893–5PubMedCrossRef

86.

Choi S, Park YI, Lee SK, et al. Aloesin inhibits hyperpigmentation induced by UV radiation. Clin Exp Dermatol 2002; 27: 513–5PubMedCrossRef

Titel: Postinflammatory Hyperpigmentation
Etiologic and Therapeutic Considerations
verfasst von: Valerie D. Callender, MD
Sharleen St. Surin-Lord
Erica C. Davis
Marissa Maclin
Publikationsdatum: 01.04.2011
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 2/2011
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.2165/11536930-000000000-00000

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

22.04.2024 | DGIM 2024 | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Postinflammatory Hyperpigmentation

Etiologic and Therapeutic Considerations

Abstract

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

New Interleukin-23 Pathway Inhibitors in Dermatology

Inverse Psoriasis

Malignant Melanoma

Nail Disorders in Children

Resveratrol-Containing Gel for the Treatment of Acne Vulgaris

Response to Narrow-Band UVB — Vitiligo-Melasma Versus Vitiligo

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie